Lanifibranor is a small molecule commercialized by Inventiva, with a leading Phase III program in Non-Alcoholic Steatohepatitis (NASH). According to Globaldata, it is involved in 10 clinical trials, of which 6 were completed, 3 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Lanifibranor’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Lanifibranor is expected to reach an annual total of $730 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Lanifibranor Overview

Lanifibranor is under development for the treatment of non alcoholic fatty liver disease (NAFLD), type 2 diabetes, compensated cirrhosis, liver fibrosis, non-alcoholic steatohepatitis. It is administered through oral route in the form of tablet. It is a new chemical entity. The drug candidate targets (PPAR) peroxisome proliferator-activated receptors (PPAR-alpha, PPAR-gamma and PPAR -delta receptors). It is under development for type 2 diabetes. It was also under development for the treatment of diabetes and systemic sclerosis. It was also under development for the treatment of idiopathic pulmonary fibrosis.

Inventiva Overview

Inventiva is a biopharmaceutical company The company discovers and develops therapies for fibrosis, oncology and lysosomal storage disorders. It’s pipeline products include lanifibranor for non-alcoholic steatohepatitis, odiparcil for mucopolysaccharidosis, ABBV-157 for moderate to severe psoriasis, hippo for non-small cell lung Cancer and mesothelioma, and GEV for idiopathic pulmonary fibrosis. It develops compounds that target nuclear receptors, transcription factors and epigenetic modulation. The company has two innovative clinical programs that are NATIVE and IMPROVES. It conducts its drug discovery research and development in partnership with various medical organizations such as AbbVie, Abbott, Solvay, Fournier. Inventiva is headquartered in Daix, France.

The company reported revenues of (Euro) EUR4.2 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of EUR0.4 million in FY2020. The operating loss of the company was EUR52.1 million in FY2021, compared to an operating loss of EUR29.7 million in FY2020. The net loss of the company was EUR49.6 million in FY2021, compared to a net loss of EUR33.6 million in FY2020.

For a complete picture of Lanifibranor’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.